ArticleJournal of virology2020
Astrovirus Replication Is Inhibited by Nitazoxanide
Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- The neonatal Fc receptor is a cellular receptor for human astrovirus.Nature microbiology · 2024Article
- Antiviral Activity of Nitazoxanide and Miltefosine Against FeHV-1 In Vitro.Veterinary medicine international · 2024Article
- Therapeutic potential of salicylamide derivatives for combating viral infections.Medicinal research reviews · 2023Review
- Diversity and Genetic Characteristics of Astroviruses from Animals in Yunnan Province.Viruses · 2022Article
- Aspects of Antiviral Strategies Based on Different Phototherapy Approaches: Hit by the Light.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Astrovirus-induced epithelial-mesenchymal transition via activated TGF-β increases viral replication.PLoS pathogens · 2022Article
- Structures of Two Human Astrovirus Capsid/Neutralizing Antibody Complexes Reveal Distinct Epitopes and Inhibition of Virus Attachment to Cells.Journal of virology · 2022Article
- Current and Future Antiviral Strategies to Tackle Gastrointestinal Viral Infections.Microorganisms · 2021Review
- Neurotropic Astroviruses in Animals.Viruses · 2021Review
- Review
- Beyond the Gastrointestinal Tract: The Emerging and Diverse Tissue Tropisms of Astroviruses.Viruses · 2021Review
- Human Astroviruses: A Tale of Two Strains.Viruses · 2021Article
- Interferon-inducer antivirals: Potential candidates to combat COVID-19.International immunopharmacology · 2021Review
- Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?Journal, genetic engineering & biotechnology · 2020Review
- A Review on SARS-CoV-2 Virology, Pathophysiology, Animal Models, and Anti-Viral Interventions.Pathogens (Basel, Switzerland) · 2020Review
- Astrovirus Replication Is Inhibited by NitazoxanideJournal of virology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Astroviruses (AstV) are a leading cause of diarrhea, especially in the very young, the elderly, and immunocompromised populations. Despite their significant impact on public health, no drug therapies for astrovirus have been identified. In this study, we fill this gap in knowledge and demonstrate that the FDA-approved broad-spectrum anti-infective drug nitazoxanide (NTZ) blocks astrovirus replication
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.